
Supriya Lifescience Ltd is Rated Sell
2026-11-17 10:10:27Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 2 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 November 2026, providing investors with the most recent and relevant data to assess the company’s outlook.
Read More
Supriya Lifescience Ltd Hits Intraday Low Amid Price Pressure on 9 Nov 2026
2026-11-09 10:22:00Supriya Lifescience Ltd experienced a notable decline today, touching an intraday low of Rs 602.45, reflecting a sharp price pressure of -7.51%. The stock underperformed its sector and broader market indices, continuing a downward trend that has persisted over the last three sessions.
Read MoreSupriya Lifescience Drops 17.76% Amid Technical Shifts and Valuation Concerns
2026-11-07 12:01:41Key Events This Week 2 Nov: Stock opens at ₹838.30, down 0.93% amid mixed market signals 3 Nov: Technical momentum shifts to sideways; stock closes at ₹832.35 (-0.71%) 4 Nov: Strong rebound with 3.41% gain to ₹860.70 on renewed buying interest 5 Nov: Mildly bullish technical stance; stock rises 1.01% to ₹869.40 6 Nov: Sharp plunge of 19.96% to ₹695.90; hits lower circuit amid heavy selling <div class="stat-labe...
Read More
Supriya Lifescience Ltd Locks at Lower Circuit With 20% Loss — Sellers Queue, No Buyers in Sight
2026-11-06 14:00:08At Rs 704.05, Supriya Lifescience Ltd locked at its lower circuit limit of 20% on 6 Nov 2026, with sellers lined up but no buyers willing to absorb the supply. This freeze at the floor price reflects unfilled sell orders and a market unable to find demand at these levels.
Read More
Supriya Lifescience Ltd Hits Intraday Low Amid Price Pressure on 6 Nov 2026
2026-11-06 13:03:22Supriya Lifescience Ltd experienced a notable decline in intraday trading on 6 Nov 2026, touching a low of Rs 774.1, reflecting a sharp price correction amid broader market gains. The stock underperformed its sector and the benchmark Sensex, signalling immediate selling pressure and subdued market sentiment towards the small-cap pharmaceutical firm.
Read More
Supriya Lifescience Ltd is Rated Sell
2026-11-06 10:11:34Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Nov 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 November 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Supriya Lifescience Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals
2026-11-05 08:06:37Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite this positive directional change, key technical indicators such as MACD and KST remain mildly bearish on weekly and monthly timeframes, while moving averages on the daily chart suggest emerging strength. This nuanced technical landscape warrants a detailed analysis for investors navigating the Pharmaceuticals & Biotechnology sector.
Read More
Supriya Lifescience Ltd is Rated Hold by MarketsMOJO
2026-10-26 10:10:26Supriya Lifescience Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Supriya Lifescience Ltd Valuation Shifts Signal Changing Market Sentiment
2026-10-22 08:01:51Supriya Lifescience Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings and price-to-book value ratios, prompting investors to reassess the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.
Read MoreAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
13-Nov-2026 | Source : BSEEarnings Call Transcript is enclosed herewith.
Announcement under Regulation 30 (LODR)-Newspaper Publication
07-Nov-2026 | Source : BSENewspaper Advertisement enclosed herewith.
Board Meeting Outcome for Outcome Of Board Meeting For Quarter And Half Year Ended Ended September 30 2026.
06-Nov-2026 | Source : BSEPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of the Company at its Meeting held on Friday November 6 2026 inter-alia to considered and approved the following:
Corporate Actions
No Upcoming Board Meetings
Supriya Lifescience Ltd has declared 50% dividend, ex-date: 04 Sep 26
No Splits history available
No Bonus history available
No Rights history available